Simplified Chinese
Du Weimin, Executive Director of Minhai Biotechnology, and his delegation paid a visit to the National Institute for Food and Drug Control for a symposium and exchange.
Release date:
2021-03-10
Author:
Source:
Abstract
2021 year 3 month 8 In the afternoon, a delegation of company leaders—including Executive Director Du Weimin, Executive Deputy General Manager Liu Jiankai, Chief Scientist Zeng Ming, and Deputy General Manager Huang Zhilu—visited the National Institute for Food and Drug Control for a symposium and exchange. They were received by Li Bo, Director-General of the Drug Administration of the National Medical Products Administration and President of the National Institute for Food and Drug Control, who extended a warm welcome.
Executive Director Du Weimin provided a detailed briefing to the leadership of the National Institute for Food and Drug Control on the development histories and project progress of Shenzhen Kangtai and Minhai Biotechnology, as well as the companies’ future development plans and strategic positioning. The attending leaders unanimously commended the companies’ achievements and engaged in an in-depth discussion on their key COVID‑19 vaccine projects.
Dean Li Bo offered constructive guidance on our company’s COVID‑19 vaccine research and development, management practices, and future prospects. It was pointed out that epidemic prevention and control must remain a top priority, and that the important instructions of General Secretary Xi Jinping on the COVID‑19 vaccine series must be earnestly implemented. We will treat the successful development of a COVID‑19 vaccine as our top priority, devote all our efforts to supporting the overall epidemic prevention and control effort, and accelerate the process of bringing the vaccine to market.
Following the meeting, General Manager Du stated that the company will remain committed to its mission of “developing superior vaccines to benefit human health,” with quality and safety as its foundation and R&D innovation as its driving force. The company will strive to become a leading domestic and internationally renowned large-scale biopharmaceutical multinational corporation, making even greater contributions to the global immunization effort and to the nation at large.
Keywords:
Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account